#kidney

The single-tablet antiretroviral regimen includes Janssen’s darunavir plus Gilead’s cobicistat, emtricitabine and tenofovir alafenamide.

That’s compared with HIV-negative men.

It’s the NIH’s first large-scale clinical trial on the subject. Plus: Meet organ transplant advocate Mo Murray [VIDEO].

A new analysis finds that Gilead Sciences’ updated version of its key antiretroviral tenofovir may not actually offer any safety benefits.

Additionally, in a recent study, having hep C mutations associated with resistance didn’t affect the outcome of treatment.

In a randomized comparison trial, those who switched from Epzicom to Descovy had a comparable rate of HIV suppression.

Compared with their HIV-negative peers, HIV-positive individuals have higher rates of treatment for a host of health problems.

HIV-positive to HIV-positive transplants are now possible for people living with the virus.

A recent study analyzed kidney parameters among those with HIV who were treated for hep C with the regimen.

Highlights from HIV and hepatitis C research presented at the 2018 Conference on Retroviruses and Opportunistic Infections (CROI) in Boston

Forty-eight-week results are in from a Phase III study that switched participants from Triumeq to Gilead’s new single-tablet regimen.

The once-daily regimen includes the integrase inhibitor bictegravir plus the contents of Descovy (emtricitabine/tenofovir alafenamide).

Organ transplants between HIV-positive people have taken place since 2016—but until now, the donors were deceased.

Among the hep C population, other factors associated with chronic kidney disease include being older and having diabetes or HIV.

The single-tablet regimen contains ViiV’s Tivicay (dolutegravir) and Janssen’s Edurant (rilpivirine).

A new large study compared the single-tablet regimen with an equivalent containing a different version of tenofovir.